Keymed Biosciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	716.31	428.12	354.1	100.06	110.27
Revenue Growth (YoY)	67.31%	20.91%	253.87%	-9.26%	-
Cost of Revenue	88.05	12.2	36.88	2.59	17.2
Gross Profit	628.27	415.92	317.22	97.48	93.07
Selling, General & Admin	504.2	298.83	177.01	133.91	92.45
Research & Development	723.53	735.19	596.28	507.37	358.16
Other Operating Expenses	62.91	7.99	1.36	0.68	2.96
Operating Expenses	1,291	1,042	774.65	641.97	453.57
Operating Income	-662.37	-626.09	-457.43	-544.49	-360.5
Interest Expense	-16.91	-18.46	-17.26	-8.4	-11.13
Interest & Investment Income	-	88.33	88.35	54.32	7.01
Earnings From Equity Investments	-0.67	-5.26	-4.75	-9.71	-0.72
Currency Exchange Gain (Loss)	-	18.15	11.08	139.03	-54.72
Other Non Operating Income (Expenses)	159.22	34.62	23.82	65.66	-13.78
EBT Excluding Unusual Items	-520.72	-508.71	-356.19	-303.6	-433.84
Gain (Loss) on Sale of Investments	-	0.06	-	-	-
Other Unusual Items	-	-	-	-	-3,459
Pretax Income	-520.72	-508.65	-356.19	-303.6	-3,893
Income Tax Expense	1.87	6.26	1.6	-	-
Earnings From Continuing Operations	-522.6	-514.91	-357.79	-303.6	-3,893
Minority Interest in Earnings	-0.04	-0.33	-1.57	-4.52	5.32
Net Income	-522.64	-515.24	-359.36	-308.12	-3,887
Net Income to Common	-522.64	-515.24	-359.36	-308.12	-3,887
Shares Outstanding (Basic)	274	262	261	261	161
Shares Outstanding (Diluted)	274	262	261	261	161
Shares Change (YoY)	4.46%	0.22%	0.09%	62.34%	139.72%
EPS (Basic)	-1.91	-1.97	-1.37	-1.18	-24.17
EPS (Diluted)	-1.91	-1.97	-1.37	-1.18	-24.17
Free Cash Flow	-	-997.55	-682.11	-680.76	-386.42
Free Cash Flow Per Share	-	-3.81	-2.61	-2.61	-2.40
Gross Margin	87.71%	97.15%	89.59%	97.42%	84.40%
Operating Margin	-92.47%	-146.24%	-129.18%	-544.15%	-326.93%
Profit Margin	-72.96%	-120.35%	-101.49%	-307.92%	-3525.30%
Free Cash Flow Margin	-	-233.00%	-192.63%	-680.33%	-350.44%
EBITDA	-587.35	-551.07	-405.8	-522.22	-347.7
EBITDA Margin	-82.00%	-128.72%	-114.60%	-	-
D&A For EBITDA	75.01	75.01	51.63	22.27	12.8
EBIT	-662.37	-626.09	-457.43	-544.49	-360.5
EBIT Margin	-92.47%	-146.24%	-129.18%	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.